Free Trial
OTCMKTS:MYMX

Mymetics (MYMX) Stock Price, News & Analysis

$0.0003 0.00 (0.00%)
As of 10/15/2025

About Mymetics Stock (OTCMKTS:MYMX)

Advanced

Key Stats

Today's Range
$0.0003
$0.0003
50-Day Range
N/A
52-Week Range
$0.0003
$0.0003
Volume
N/A
Average Volume
13 shs
Market Capitalization
$45.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mymetics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MYMX Stock News Headlines

Sp Bmv Ipc Esg Tilted Heavy (MYMX)
PLTXF PlantX Life Inc.
Is *BSEM* Oversold??
BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The company delivered record-breaking revenues in 2024 and Q1 2025, including $72.5 million in net revenue for Q1 — a 73% increase over the prior year — and six consecutive quarters of positive adjusted EBITDA. With cash reserves rising to $30.8 million and a growing patent portfolio of 58 issued and 68 pending patents, BSEM is scaling profitably while advancing its proprietary BioREtain® technology, which has shown clinically superior results for chronic, non-healing wounds. National recognition is adding to the momentum, with CEO Jason Matuszewski named EY Entrepreneur of the Year 2025 Florida Award winner, validating the leadership driving this high-growth MedTech powerhouse.tc pixel
Mymetics Stock (OTC:MYMX), Short Interest Report
Mymetics Corporation (MYMX)
See More Headlines

MYMX Stock Analysis - Frequently Asked Questions

Mymetics' stock was trading at $0.0010 at the start of the year. Since then, MYMX stock has decreased by 70.0% and is now trading at $0.0003.

Shares of MYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mymetics investors own include Dynavax Technologies (DVAX), Fujitsu (FJTSY), Genocea Biosciences (GNCA), Maxar Technologies (MAXR), Revance Therapeutics (RVNC), Axcelis Technologies (ACLS) and Allied Gaming & Entertainment (AGAE).

Company Calendar

Today
10/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:MYMX
CIK
927761
Employees
8
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.08 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
150,000
Free Float
144,000
Market Cap
$45.00
Optionable
Not Optionable
Beta
2.51
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (OTCMKTS:MYMX) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners